Akili Valuation
Is AKLI * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AKLI * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AKLI *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AKLI *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AKLI *?
Other financial metrics that can be useful for relative valuation.
What is AKLI *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$34.01m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AKLI *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 4.2x | ||
ICAD iCAD | 1.7x | 18.0% | US$33.3m |
RHT Reliq Health Technologies | 3.2x | n/a | CA$47.3m |
JRSS JRSIS Health Care | 9.8x | n/a | US$34.0m |
XYBN Xybion Digital | 2x | n/a | CA$47.2m |
AKLI * Akili | 17.5x | 44.2% | Mex$34.0m |
Price-To-Sales vs Peers: AKLI * is expensive based on its Price-To-Sales Ratio (17.5x) compared to the peer average (4.2x).
Price to Earnings Ratio vs Industry
How does AKLI *'s PE Ratio compare vs other companies in the Global Healthcare Services Industry?
Price-To-Sales vs Industry: AKLI * is expensive based on its Price-To-Sales Ratio (17.5x) compared to the Global Healthcare Services industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is AKLI *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 17.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AKLI *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.